These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 29737248)

  • 21. Berberine slows cell growth in autosomal dominant polycystic kidney disease cells.
    Bonon A; Mangolini A; Pinton P; Del Senno L; Aguiari G
    Biochem Biophys Res Commun; 2013 Nov; 441(3):668-74. PubMed ID: 24184483
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease: A Biomarker of Disease Progression and Therapeutic Efficacy.
    Alam A; Dahl NK; Lipschutz JH; Rossetti S; Smith P; Sapir D; Weinstein J; McFarlane P; Bichet DG
    Am J Kidney Dis; 2015 Oct; 66(4):564-76. PubMed ID: 25960302
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pathophysiology, epidemiology, clinical presentation, diagnosis and treatment options for autosomal dominant polycystic kidney disease].
    Noël N; Rieu P
    Nephrol Ther; 2015 Jul; 11(4):213-25. PubMed ID: 26113401
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent advances in autosomal-dominant polycystic kidney disease.
    Rangan GK; Tchan MC; Tong A; Wong AT; Nankivell BJ
    Intern Med J; 2016 Aug; 46(8):883-92. PubMed ID: 27553994
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent Discoveries in Epigenetic Modifications of Polycystic Kidney Disease.
    Bowden SA; Rodger EJ; Chatterjee A; Eccles MR; Stayner C
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948126
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Autosomal dominant polycystic kidney disease: new insights into treatment.
    Helal I
    Saudi J Kidney Dis Transpl; 2013 Mar; 24(2):230-4. PubMed ID: 23538343
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transcriptome analysis reveals manifold mechanisms of cyst development in ADPKD.
    de Almeida RM; Clendenon SG; Richards WG; Boedigheimer M; Damore M; Rossetti S; Harris PC; Herbert BS; Xu WM; Wandinger-Ness A; Ward HH; Glazier JA; Bacallao RL
    Hum Genomics; 2016 Nov; 10(1):37. PubMed ID: 27871310
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [New therapies for ADPKD].
    Rathaus M
    G Ital Nefrol; 2007; 24(6):526-34. PubMed ID: 18278756
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanisms and management of hypertension in autosomal dominant polycystic kidney disease.
    Rahbari-Oskoui F; Williams O; Chapman A
    Nephrol Dial Transplant; 2014 Dec; 29(12):2194-201. PubMed ID: 24463189
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent Trends in ADPKD Research.
    Shin YB; Park JH
    Adv Exp Med Biol; 2016; 933():3-11. PubMed ID: 27730430
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors of rapid disease progression in autosomal dominant polycystic kidney disease.
    Corradi V; Gastaldon F; Caprara C; Giuliani A; Martino F; Ferrari F; Ronco C
    Minerva Med; 2017 Feb; 108(1):43-56. PubMed ID: 27701376
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular and cellular pathogenesis of autosomal dominant polycystic kidney disease.
    Bastos AP; Onuchic LF
    Braz J Med Biol Res; 2011 Jul; 44(7):606-17. PubMed ID: 21625823
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted rescue of a polycystic kidney disease mutation by lysosomal inhibition.
    Hofherr A; Wagner CJ; Watnick T; Köttgen M
    Kidney Int; 2016 Apr; 89(4):949-55. PubMed ID: 26924047
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent Advances of mTOR Inhibitors Use in Autosomal Dominant Polycystic Kidney Disease: Is the Road Still Open?
    Kou P; Wei S; Xiong F
    Curr Med Chem; 2019; 26(16):2962-2973. PubMed ID: 29600752
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Somatostatin in renal physiology and autosomal dominant polycystic kidney disease.
    Messchendorp AL; Casteleijn NF; Meijer E; Gansevoort RT
    Nephrol Dial Transplant; 2020 Aug; 35(8):1306-1316. PubMed ID: 31077332
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug Development in Autosomal Dominant Polycystic Kidney Disease: Opportunities and Challenges.
    Chebib FT; Perrone RD
    Adv Kidney Dis Health; 2023 May; 30(3):261-284. PubMed ID: 37088528
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial.
    Gevers TJ; Hol JC; Monshouwer R; Dekker HM; Wetzels JF; Drenth JP
    Liver Int; 2015 May; 35(5):1607-14. PubMed ID: 25369108
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Double inhibition of cAMP and mTOR signalling may potentiate the reduction of cell growth in ADPKD cells.
    de Stephanis L; Bonon A; Varani K; Lanza G; Gafà R; Pinton P; Pema M; Somlo S; Boletta A; Aguiari G
    Clin Exp Nephrol; 2017 Apr; 21(2):203-211. PubMed ID: 27278932
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A high-throughput screening platform for Polycystic Kidney Disease (PKD) drug repurposing utilizing murine and human ADPKD cells.
    Asawa RR; Danchik C; Zakharov A; Chen Y; Voss T; Jadhav A; Wallace DP; Trott JF; Weiss RH; Simeonov A; Martinez NJ
    Sci Rep; 2020 Mar; 10(1):4203. PubMed ID: 32144367
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elamipretide treatment during pregnancy ameliorates the progression of polycystic kidney disease in maternal and neonatal mice with PKD1 mutations.
    Daneshgar N; Liang PI; Lan RS; Horstmann MM; Pack L; Bhardwaj G; Penniman CM; O'Neill BT; Dai DF
    Kidney Int; 2022 May; 101(5):906-911. PubMed ID: 34953771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.